MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
最新数据
JP¥710
+JP¥14.00 · +2.01%
盘中时间采用JST。市场数据可能有所延迟。
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
日内区间
当前JP¥710
52周区间
当前JP¥710
盘中时间采用JST。市场数据可能有所延迟。
MabGenesis Inc., a biopharmaceutical company, engages in the research, discovery, development, and commercialization of therapeutic monoclonal antibody drugs for human and animal healthcare applications in Japan. The company offers proprietary antibody discovery platforms, including MOURA Libraries and IMPACT antibody isolation technology, to develop antibody therapeutics. The company was incorporated in 2019 and is based in Yokohama, Japan.
日内区间
当前JP¥710
52周区间
当前JP¥710
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
